Saturday 17 October 2026
Export ORGS’s income statement to Excel — free account
Orgenesis Inc.
ORGS Healthcare Biotechnology
Orgenesis Inc.’s revenue for fiscal 2024 (year ended December 2024) was $1.0 million, up 95.3% from fiscal 2023. In the quarter to December 2024, revenue grew 82.4%, EPS fell 211.9% and free cash flow fell 317.9%, each against the same quarter a year earlier.
0.06
0.06
Infinity
Follow ORGS
| Older periods | Mar '24 | Jun '24 | Sep '24 | Dec '24 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
36.44 | 38.10 | 23.39 | 7.69 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(4.34) | (4.27) | (4.54) | (3.79) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
84.55 | 53.23 | 38.98 | 23.15 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.72) | (2.93) | (2.26) | (1.40) | |
EV/FCF |
(3.43) | (2.81) | (2.23) | (1.38) | |
Quick Ratio |
0.03 | 0.04 | 0.04 | 0.03 | |
Current Ratio |
0.07 | 0.07 | 0.07 | 0.03 | |
Net Debt/EBITDA |
(2.98) | (2.83) | (1.78) | (0.90) | |
Debt/Assets |
84.14% | 36.55% | 50.98% | 1,235.53% | |
Debt/Equity |
(0.94) | (0.71) | (0.63) | (0.44) | |
Asset Turnover |
0.01 | 0.03 | 0.04 | 0.13 | |
Operating CF/Net income |
0.45 | 0.66 | 0.51 | 0.10 | |
Capex/Depreciation |
(0.54) | 0.00 | (0.11) | 0.00 | |
Interest Coverage |
(10.48) | (5.21) | (11.69) | (8.57) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
4,295.04% | 837.80% | 767.72% | 1,342.52% | |
Intangible Assets out of Total Assets |
0.33 | 0.32 | 0.33 | 0.00 | |
Share Based Compensation of Revenue |
221.28% | 253.66% | 466.57% | 212.29% | |
Graham Net Nets |
(2.93) | (1.75) | (2.43) | (4.79) | |
Graham Number |
36.28 | 26.78 | 31.22 | 48.05 | |
Earnings Yield |
(121.26%) | (120.88%) | (191.35%) | (608.99%) | |
Free Cash Flow Yield |
(67.72%) | (49.71%) | (74.86%) | (217.87%) | |
Revenue per Share |
0.04 | 0.06 | 0.07 | 0.07 | |
Operating CF per Share |
(1.34) | (1.52) | (0.98) | (0.50) | |
Capex per Share |
(0.06) | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(1.40) | (1.52) | (0.99) | (0.50) | |
Cash per Share |
0.17 | 0.30 | 0.24 | 0.16 | |
Shareholders Equity per Share |
(8.30) | (4.06) | (5.07) | (8.91) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(8.30) | (4.06) | (5.07) | (8.91) | |
Free Cash Flow |
(4.64) | (5.91) | (4.69) | (2.10) | |
Working Capital |
(27.07) | (29.35) | (33.53) | (26.16) | |
Capital Expenditures |
(0.20) | 0.00 | (0.06) | 0.00 | |
Net Current Asset Value |
(56.51) | (44.02) | (51.10) | (38.12) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
1.45 | 0.00 | 0.17 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
10.80 | 0.61 | 0.64 | 0.29 | |
Average Payables |
10.40 | 8.69 | 9.51 | 9.85 | |
Average Inventory |
0.08 | — | — | — | |
Average Assets |
52.54 | 24.32 | 23.61 | 7.95 | |
Average Common Equity |
(8.78) | (14.26) | (19.65) | (29.26) |
Columns are period end dates